Programs

A preclinical ocular pipeline built from delivery access and disease biology.

The pipeline is organized around local ocular compartments where AAV‑IKV, Nuc1, and disease‑matched payloads can be evaluated in defined biological models.

ProgramBiologyDelivery routeStatus

AAV‑IKV retinal penetrating AAVPlatformOuter retinal access; photoreceptors and RPEIntravitreal deliveryPlatform validation

Glaucoma: AAV‑IKV‑DecorinLead glaucoma programTGFβ2 / decorin axis; trabecular meshwork fibrosis; IOP biologyIntracameral delivery to anterior segmentPreclinical

Wet AMD: AAV‑IKV‑DecorinRetinal disease programCNV, subretinal fibrosis, inflammation, autophagyIntravitreal delivery to outer retinaPreclinical

Dry AMD: undisclosed complement programNovel complement targetingLocal complement modulation for dry AMD / geographic atrophy biologyUndisclosed ocular delivery strategyDiscovery

Undisclosed retinal degeneration treatmentRetinal disease programUndisclosed disease-modifying biologyRetinal delivery platform fitDiscovery

Nuc1-enabled biologicsProtein / large-molecule deliveryIntracellular retinal delivery of biologics and other cargoIntravitreal and topical ocular research settingsPlatform validation

Program detail

Therapeutic hypotheses under preclinical evaluation.

Retinal penetrating AAV

AAV‑IKV platform

AAV‑IKV is the delivery basis for retinal programs where payload expression is intended in outer retinal cell types reached from the vitreous.

Intravitreal route in retinal studies
Photoreceptor and RPE expression in published murine work
Payload strategy includes decorin, complement biology, and undisclosed retinal degeneration programs

Wet AMD

AAV‑IKV‑Decorin

The wet AMD study program emphasizes decorin biology across neovascularization and fibrosis, with additional inflammatory and autophagy readouts.

Laser‑induced CNV model
Reduction of CNV and fibrotic markers in published work
Therapeutic concept beyond VEGF-only mechanisms

Dry AMD

Undisclosed complement-targeted treatment

The dry AMD program is undisclosed, but is directed at local complement modulation for dry AMD and geographic atrophy biology.

Complement-targeted payload biology
Ocular delivery strategy under evaluation
Built on relevant founder experience in complement gene therapy for dry AMD

Glaucoma emphasis

AAV‑IKV‑Decorin addresses outflow tissue fibrosis.

The glaucoma program is intentionally separated from neuroprotection-only approaches. It focuses on trabecular meshwork remodeling, decorin expression, and local anterior segment delivery.

Glaucoma science

TGFβ2→EMT / fibrosis

Fibrosis→outflow resistance

AAV‑IKV‑Decorin→local anti‑fibrotic expression